Opportunity Information: Apply for RFA DP 16 002
Apply for RFA DP 16 002
- The HHS-CDC-HHSCDCERA in the health sector is offering a public funding opportunity titled "Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283.
- This funding opportunity was created on Dec 07, 2015 and posted on Dec 07, 2015.
- Applicants must submit their applications by Feb 05, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study is a CDC-funded cooperative agreement designed to deepen the public health understanding of systemic lupus erythematosus (SLE) by following people over time in an established, population-based cohort in Michigan. The opportunity exists because lupus, while often discussed as a single condition, can range from relatively limited disease to severe, multi-organ illness that leads to significant disability and early death. SLE is the most common and most serious form, and it affects a large and uncertain number of Americans (estimates range from roughly 320,000 to 1.5 million). It also shows pronounced disparities, with women affected far more often than men and racial and ethnic minority groups carrying a higher burden than white populations. Despite this impact, much of the existing knowledge base comes from tertiary care centers and convenience samples that tend to over-represent severe cases, leaving major gaps in understanding the full spectrum of disease in the community.
The central aim of the grant is to support a longitudinal study that tracks outcomes in a population-based group of individuals with confirmed SLE, rather than relying on referral centers that may not represent typical cases. The funded work is intended to document, over time, how SLE is treated in real-world settings, how patients access and use health care, and how the disease naturally progresses. This includes measuring changes in disease severity and complications, as well as major endpoints like morbidity and mortality. By following the same participants across multiple time points, the study can capture patterns that cross-sectional snapshots miss, such as flares and remissions, treatment changes, cumulative organ damage, and longer-term survival.
A second major focus is identifying factors that are associated with differences in outcomes. The opportunity explicitly highlights genetic and other biological contributors, including antibody levels and related biomarkers, as well as broader influences that may help explain why some patients do better than others. This emphasis reflects the complexity of SLE, where outcomes can be shaped by biology, environment, hormones, comorbidities, and response to therapy. In practice, the funded project would be expected to examine how these factors relate to treatment effectiveness, disease progression, and the ability to obtain appropriate care.
A third priority is evaluating disparities and other differences in outcomes across key groups of interest, such as by gender and race/ethnicity. This includes not only documenting whether disparities exist, but also exploring what might be driving them, for example differences in access to specialists, insurance coverage, timeliness of diagnosis, treatment patterns, adherence barriers, environmental exposures, or biologic risk. Because the cohort is population-based, the findings are intended to be more generalizable and less skewed toward the most severe cases, making the results more useful for designing equitable public health and clinical interventions.
From an administrative standpoint, this was a discretionary funding opportunity offered by the U.S. Department of Health and Human Services through the CDC (CFDA 93.283). The funding mechanism is a cooperative agreement, which generally means the CDC would have substantial involvement in the project compared with a traditional grant, often through collaboration on study design elements, data standards, reporting, and public health deliverables. The opportunity (RFA DP 16-002) anticipated a single award, with an award ceiling of $1,000,000. The posting and creation dates were December 7, 2015, and the application closing date was February 5, 2016. Eligibility was listed broadly as "Others" with additional clarification in the full announcement, signaling that eligibility likely depended on specific institutional or partnership qualifications described in the complete RFA.
Overall, the MILES longitudinal cohort study opportunity is about building a stronger, more accurate epidemiologic picture of SLE as it actually occurs in the population, then using that foundation to understand real-world care, long-term outcomes, and the drivers of unequal burden across communities. The intended payoff is evidence that can inform better surveillance, targeted interventions, improved access to care, and ultimately reduced morbidity and mortality for people living with lupus.
Frequently Asked Questions (FAQs): Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study
What is the MILES Program Longitudinal Cohort Study grant opportunity?
The Michigan Lupus Epidemiology and Surveillance (MILES) Program Longitudinal Cohort Study is a CDC-funded cooperative agreement intended to deepen public health understanding of systemic lupus erythematosus (SLE) by following people over time in an established, population-based cohort in Michigan.
Which federal agency is offering this opportunity?
This opportunity was offered by the U.S. Department of Health and Human Services (HHS) through the Centers for Disease Control and Prevention (CDC).
What is the funding mechanism for this award?
The funding mechanism is a cooperative agreement. This typically means CDC has substantial involvement compared with a traditional grant, often including collaboration on study design elements, data standards, reporting, and public health deliverables.
What is the main purpose of the funded work?
The central aim is to support a longitudinal study that tracks outcomes in a population-based group of individuals with confirmed SLE, documenting real-world treatment, health care access and use, and how the disease progresses over time.
Why does the opportunity emphasize a population-based cohort?
The opportunity notes that much existing knowledge comes from tertiary care centers and convenience samples that tend to over-represent severe cases. A population-based cohort is intended to provide a more accurate picture of the full spectrum of SLE as it occurs in the community and to produce findings that are more generalizable.
What is systemic lupus erythematosus (SLE) in the context of this opportunity?
SLE is described as the most common and most serious form of lupus. The opportunity highlights that lupus can range from relatively limited disease to severe multi-organ illness that can cause significant disability and early death.
Why is this research considered important from a public health perspective?
The opportunity points to the large and uncertain number of Americans affected (estimates ranging from roughly 320,000 to 1.5 million), the potential for severe outcomes, and pronounced disparities across gender and racial/ethnic groups. It also notes gaps in understanding due to prior research being skewed toward more severe cases.
What kinds of outcomes is the longitudinal study intended to measure?
The funded work is intended to measure how SLE changes over time, including changes in disease severity and complications, major endpoints like morbidity and mortality, and patterns such as flares and remissions, treatment changes, cumulative organ damage, and longer-term survival.
How is a longitudinal study different from a cross-sectional study in this context?
The opportunity emphasizes that following the same participants across multiple time points allows the study to capture patterns that cross-sectional snapshots can miss, such as flares/remissions, treatment changes, cumulative damage, and survival over longer periods.
What is meant by studying "real-world" SLE treatment and care?
In this opportunity, real-world study refers to documenting how SLE is treated in routine settings and how patients access and use health care, rather than relying on referral centers that may not reflect typical cases.
What is the second major focus of the opportunity besides tracking outcomes over time?
A second major focus is identifying factors associated with differences in outcomes. The opportunity explicitly highlights genetic and other biological contributors, including antibody levels and related biomarkers, along with broader influences that may help explain why outcomes differ across individuals.
What types of contributors to different SLE outcomes are highlighted?
The opportunity highlights genetic and other biological contributors (including antibody levels and biomarkers) and notes that outcomes may also be shaped by factors such as environment, hormones, comorbidities, and response to therapy.
How are health care access and use expected to fit into the study?
The opportunity states that the work should document how patients access and use health care, and it frames access to appropriate care as a key part of understanding differences in outcomes and disparities.
What is the third major priority of the grant?
The third priority is evaluating disparities and other differences in outcomes across key groups of interest, such as by gender and race/ethnicity, and exploring what might be driving those differences.
Which disparities or subgroup comparisons are specifically mentioned?
The opportunity specifically mentions differences by gender and by race/ethnicity, noting that women are affected far more often than men and that racial and ethnic minority groups carry a higher burden than white populations.
What kinds of potential drivers of disparities does the opportunity mention?
Examples mentioned include differences in access to specialists, insurance coverage, timeliness of diagnosis, treatment patterns, adherence barriers, environmental exposures, and biologic risk.
How does the opportunity frame the expected value of the population-based approach for equity?
Because the cohort is population-based and less skewed toward the most severe cases, the opportunity suggests findings should be more useful for designing equitable public health and clinical interventions.
What is the program trying to improve or inform with its findings?
The intended payoff is evidence that can inform better surveillance, targeted interventions, improved access to care, and ultimately reduced morbidity and mortality for people living with lupus.
What is the RFA identifier for this opportunity?
The opportunity is identified as RFA DP 16-002.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.283.
How many awards were anticipated?
The opportunity anticipated a single award.
What was the maximum funding level mentioned?
The award ceiling listed was $1,000,000.
When was the opportunity posted and when did it close?
The posting and creation dates were December 7, 2015, and the application closing date was February 5, 2016.
Who was eligible to apply based on the provided information?
Eligibility was listed broadly as "Others," with additional clarification said to be provided in the full announcement. This indicates eligibility likely depended on specific institutional or partnership qualifications described in the complete RFA.
What geographic setting is directly referenced for the cohort?
The cohort is described as an established, population-based cohort in Michigan.
What disease burden details are provided that motivate this work?
The opportunity notes that SLE can be severe and multi-organ, that it can lead to significant disability and early death, and that the number of Americans affected is uncertain with estimates ranging from roughly 320,000 to 1.5 million. It also emphasizes pronounced disparities by gender and race/ethnicity.
Why does the opportunity mention tertiary care centers and convenience samples?
They are cited as sources for much existing knowledge that tend to over-represent severe cases, contributing to gaps in understanding the full spectrum of disease in the community.
What kinds of endpoints are explicitly named in the opportunity description?
The opportunity explicitly names morbidity and mortality as major endpoints, along with measurement of changes in disease severity, complications, and longer-term survival.
Does the opportunity describe what types of biological measures may be considered?
Yes. It specifically mentions antibody levels and related biomarkers and also references genetic and other biological contributors.
What does CDC involvement likely look like under this cooperative agreement?
Based on the description provided, CDC involvement would likely include collaboration on study design elements, data standards, reporting, and public health deliverables, reflecting a more hands-on role than a traditional grant.
What overarching gap is the opportunity trying to address?
It aims to address gaps in understanding SLE as it occurs in the broader community, including how it is treated in real-world settings, how it progresses over time, and what drives different outcomes and disparities across populations.
Browse more opportunities from the same category: Health
Next opportunity: Research on Prescription Opioid Use, Opioid Prescribing, and Associated Heroin Risk.
Previous opportunity: Health Center Controlled Networks
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DP 16 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DP 16 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research on Prescription Opioid Use, Opioid Prescribing, and Associated Heroin Risk. Apply for RFA CE 16 003 Funding Number: RFA CE 16 003 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: $400,000 |
| Centers for Disease Control and Prevention Natural History and Prevention of Viral Hepatitis among Alaska Natives Project. Apply for RFA PS 13 00104CONT16 Funding Number: RFA PS 13 00104CONT16 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: Case Dependent |
| Supporting Sustainable Implementation of HIV and TB Services for Epidemic Control in The Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1634 Funding Number: CDC RFA GH16 1634 Agency: HHS-CDC-CGH Category: Health Funding Amount: $165,000,000 |
| Provision of comprehensive HIV/AIDS services and developing national capacity to manage HIV/AIDS programs in the Republic of Uganda Apply for CDC RFA GH12 121304CONT16 Funding Number: CDC RFA GH12 121304CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Availability of Administrative Supplements to NIGMS Predoctoral Training Grants (Admin Supp) Apply for PA 16 060 Funding Number: PA 16 060 Agency: HHS-NIH11 Category: Health Funding Amount: $80,000 |
| Screening, Brief Intervention, and Referral to Treatment (SBIRT) Health Professions Student Training (SBIRT- Student Training) Apply for TI 16 002 Funding Number: TI 16 002 Agency: HHS-SAMHS Category: Health Funding Amount: $290,000 |
| Risk of Adolescence and Injury in HIV Susceptibility (RAIS) (R01) Apply for RFA AI 15 058 Funding Number: RFA AI 15 058 Agency: HHS-NIH11 Category: Health Funding Amount: $400,000 |
| Supporting Maternal and child Health Activities in Ethiopia Apply for RFI 663 16 EPCMD Funding Number: RFI 663 16 EPCMD Agency: USAID-ETH Category: Health Funding Amount: $120,000,000 |
| Guidelines for Women’s Preventive Services Apply for HRSA 16 057 Funding Number: HRSA 16 057 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Discovery/Development of Novel Therapeutics for Eukaryotic Pathogens (R21/R33) Apply for RFA AI 15 054 Funding Number: RFA AI 15 054 Agency: HHS-NIH11 Category: Health Funding Amount: $200,000 |
| Supporting the Implementation and Expansion of High Quality, Sustainable and Comprehensive HIV Prevention, Care and Treatment Programs in Faith-Based Organization Facilities in the Republic of Kenya under the President’s Emergency Plan for AIDS Rel Apply for CDC RFA GH16 1620 Funding Number: CDC RFA GH16 1620 Agency: HHS-CDC-CGH Category: Health Funding Amount: $23,000,000 |
| Defeat Malaria Apply for RFI 482 16 000001 Funding Number: RFI 482 16 000001 Agency: USAID-GHA Category: Health Funding Amount: $32,000,000 |
| ATSDR’s Program to Promote Localized Efforts to Reduce Environmental Exposure (APPLETREE) Apply for CDC RFA TS14 140303CONT16 Funding Number: CDC RFA TS14 140303CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Research on the Epidemiology, Prevention, Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in South Africa Apply for RFA IP 16 003 Funding Number: RFA IP 16 003 Agency: HHS-CDC-HHSCDCERA Category: Health Funding Amount: $5,000,000 |
| SUPPORTING THE GHANA HEALTH SERVICE (GHS) IN THE STRENGTHENING OF NATIONAL HEALTH MANAGEMENT SYSTEMS IN THE AREAS OF STRATEGIC INFORMATION SYSTEMS, BLOOD SAFETY, AND LABORATORY CAPACITY BUILDING UNDER THE PRESIDENT’S EMERGENCY PLAN FOR AIDS RELIEF Apply for CDC RFA PS10 10440501SUPP16 Funding Number: CDC RFA PS10 10440501SUPP16 Agency: HHS-CDC Category: Health Funding Amount: $3,500,000 |
| Building Capacity for Human Resources for Health in HIV/AIDS in the Republic of Kenya under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH16 1624 Funding Number: CDC RFA GH16 1624 Agency: HHS-CDC-CGH Category: Health Funding Amount: $3,200,000 |
| Improving the Capacity of University Based Medical Education and Superior Training Institutions to Provide High Quality Education in the Republic of Mozambique Under the President's Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1159SUPP Funding Number: CDC RFA GH11 1159SUPP Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pre-application: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Foundational Functional Mapping of Neuroanatomy and Neurobiology of Organs (OT1) Apply for RFA RM 15 019 Funding Number: RFA RM 15 019 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Strengthening the National Institutes of Health in the Republic of Mozambique under the President’s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1158SUPP Funding Number: CDC RFA GH11 1158SUPP Agency: HHS-CDC Category: Health Funding Amount: $5,251,408 |
| NEI Clinical Study Planning Grant Program (R34) Apply for PA 16 038 Funding Number: PA 16 038 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DP 16 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.